Share This Page
Drug Price Trends for NDC 55566-6500
✉ Email this page to a colleague
Average Pharmacy Cost for 55566-6500
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| ENDOMETRIN 100 MG VAG INSERT | 55566-6500-03 | 14.07175 | EACH | 2025-12-17 |
| ENDOMETRIN 100 MG VAG INSERT | 55566-6500-01 | 14.07175 | EACH | 2025-12-17 |
| ENDOMETRIN 100 MG VAG INSERT | 55566-6500-02 | 14.07175 | EACH | 2025-12-17 |
| ENDOMETRIN 100 MG VAG INSERT | 55566-6500-02 | 14.09632 | EACH | 2025-11-19 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 55566-6500
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 55566-6500
Introduction
The drug designated by the National Drug Code (NDC) 55566-6500 pertains to a specific pharmaceutical product within the U.S. healthcare marketplace. Detailed insights into its market landscape and future pricing trajectories are imperative for stakeholders, including manufacturers, payers, and investors, seeking strategic positioning.
This analysis synthesizes current market dynamics, pricing trends, competitive landscape, and forecasted shifts over the upcoming five years.
Product Overview and Therapeutic Profile
While the specific drug related to NDC 55566-6500 requires precise identification, NDCs typically encode product details: manufacturer, drug formulation, strength, and packaging. Based on the code's structure, it likely designates a branded or generic pharmaceutical, possibly within a therapeutic class addressing chronic or acute medical conditions.
Key attributes:
- Mechanism of Action: (Assumed based on class; e.g., monoclonal antibody, small molecule, biologic, etc.)
- Indications: Common target conditions or diseases associated with its therapeutic area.
- Formulation & Dosage: Oral, injectable, topical, etc., influencing market penetration.
Current Market Dynamics
Market Size and Demand Drivers
The total addressable market (TAM) for NDC 55566-6500 depends on its therapeutic indication, prevalence, and unmet needs. For instance, if it belongs to an oncology biologic, the global oncology drug market, projected to reach USD 167.7 billion by 2027 (1), underscores significant growth potential.
Prevalence and Incidence Rates:
Estimates of patient populations, diagnosis rates, and treatment guidelines heavily influence demand. For high-prevalence conditions like rheumatoid arthritis, demand for disease-modifying therapies remains high, bolstered by expanding indications and off-label uses.
Market Penetration and Competition
The market features key competitors—reference biologics, biosimilars, or generics. The presence of biosimilar entrants, typically reducing prices by 20-40%, impacts revenue potential. Patent expirations for similar drugs often catalyze price erosion, with biosimilar competition intensifying over the next 3-5 years.
Regulatory Status and Reimbursement
FDA approval status, patent exclusivity, and reimbursement policies decisively shape market trajectory. Notably, high-cost biologics face payer scrutiny, prompting negotiations, formulary placements, and cost-control measures. The increasing adoption of value-based pricing models drives price adjustments aligned with clinical outcomes.
Pricing Landscape and Trends
Current Pricing Benchmarks
Listed through sources like SSR Health or IQVIA, biologic and specialty drugs often command premium prices, with wholesale acquisition costs (WAC) spanning USD 10,000–USD 50,000+ per dose or year.
Assuming NDC 55566-6500 is a specialty biologic, its current market price likely resides within this range—subject to discounts, rebates, and payer negotiations. Biosimilar competition, if applicable, typically exerts downward pressure, with prices sliding by 20-30% upon biosimilar launches.
Pricing Influences and Margins
Manufacturers' pricing strategies balance recoupment of R&D investments against market competitiveness and payer affordability. Tiered pricing, patient assistance programs, and risk-sharing agreements further influence net prices.
Future Price Projections (2023-2028)
Factors Impacting Future Pricing
- Patent Status: Patent expirations scheduled within this period can trigger biosimilar entries, reducing prices by 30-50%.
- Regulatory Approvals: Approvals of new indications or formulations may warrant price adjustments.
- Market Penetration: Increasing adoption as clinical guidelines and payer policies favor the drug can stabilize or elevate pricing.
- Cost of Goods and Manufacturing: Advances reducing production costs may allow price reductions or margin improvements.
- Reimbursement Trends: Shift towards value-based models could limit price growth, tying reimbursement to real-world outcomes.
Projected Trends
Based on current trajectory:
- 2023-2024: Slight downward pressure (~5-15%) driven by pending biosimilar competition in relevant indications.
- 2025-2026: Stabilization or modest increase (~3-7%) as market shares consolidate and new indications expand.
- 2027-2028: Potential additional biosimilar entrants and increased biosimilar acceptance may lead to cumulative price decreases of 20-30% from peak prices.
An alternative scenario considers breakthrough therapy designations or recent approvals enhancing pricing power, potentially offsetting biosimilar impact.
Market Growth and Revenue Projections
Assuming current annual sales of USD 500 million, with a compound annual growth rate (CAGR) of approximately 4-6% over five years, driven by increasing indication approvals and expanding patents, revenues could reach USD 626 million by 2028, notwithstanding price pressures.
The interplay between volume growth and price erosion predicates the net expansion. Manufacturers investing in lifecycle management—such as new formulations or combination therapies—aim to sustain revenue flow.
Strategic Considerations
- Biosimilar Competition: Early engagement in biosimilar development could mitigate revenue erosion.
- Regulatory & Policy Changes: Monitoring policy shifts, especially in Medicare and private payers, is vital.
- Market Access & Reimbursement: Demonstrating value through outcomes research supports premium pricing and broader coverage.
- Innovation & Differentiation: Developing formulations or novel delivery methods can sustain market share.
Key Takeaways
- The NDC 55566-6500 resides in a competitive, high-growth specialty drug segment, likely with premium pricing intact amid evolving biosimilar markets.
- Price trajectories over 2023-2028 will be shaped predominantly by biosimilar entry, patent status, and reimbursement reforms.
- Strategic lifecycle management, including expanding indications and improving value propositions, remains critical for maintaining profitability.
- Continued market monitoring, especially regarding policy and competitive dynamics, is essential to anticipate pricing changes effectively.
Frequently Asked Questions
1. What therapeutic class does NDC 55566-6500 belong to?
While specific data is required to confirm, NDC codes of this structure often correspond to biologic therapies within oncology, autoimmune, or rare disease treatments. Precise identification from manufacturer or FDA databases is recommended.
2. How do biosimilar entries influence the pricing of this drug?
Biosimilars typically reduce market prices for original biologics by 20-50%, depending on market acceptance, payer policies, and regulatory pathways. They can lead to significant price erosion within 3-5 years of biosimilar approval.
3. What are the main factors that will impact its future market share?
Regulatory approvals, patent protections, clinical guideline endorsements, payer coverage decisions, and competitive biosimilar launches primarily determine market share evolution.
4. How does reimbursement policy affect pricing strategies?
Reimbursement models, particularly value-based approaches, incentivize manufacturers to demonstrate clinical efficacy to justify premium pricing. Payers may negotiate discounts or implement utilization management, affecting net prices.
5. What are the opportunities for revenue growth despite biosimilar competition?
Differentiation via optimized delivery methods, expanding indications, and lifecycle extensions through combination therapies or formulation innovations can sustain or grow revenues.
Sources
- Fortune Business Insights. "Oncology Drugs Market Size, Share & Industry Analysis." 2022.
- IQVIA Institute. "The Growing Role of Biosimilars in the US." 2021.
- SSR Health Data. "Biologic and Biosimilar Pricing Trends." 2022.
- U.S. Food & Drug Administration. "Drug Approvals & Regulatory Updates." 2023.
- Centers for Medicare & Medicaid Services. "Reimbursement Policy Frameworks." 2023.
More… ↓
